The Latest Breaking News from FDA

The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease

Solid foothold of personalized medicine, increasing prevalence of chronic diseases, favorable government initiatives, and rapid digital transformation are opening new avenues for biotech companies. Thus, it could be wise to invest in fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Shionogi (SGIOY), and Exelixis (EXEL)for potential gains. Read on….

Feeling sad and anxious is common after having a baby, but nearly one in eight women in a CDC study experienced a more intense depressive episode.

The CDC recommends an updated COVID booster for everyone 6 months and older.

Federal advisers met this week to discuss potential first-in-human clinical trials of artificial womb technology for preterm infants.

Warning letters sent to the companies claimed certain products they sell are ‘especially concerning from a public health perspective’

The U.S. Food and Drug Administration declined to approve a nasal spray to treat severe allergic reactions, calling for more research on what would have been the first alternative to injections using devices such as an EpiPen

Updated vaccines will be especially important to high-risk people, such as pregnant women and the elderly

Some, but not all, at-home tests have been given extended expiration dates by the FDA